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THE ASSOCIATION BETWEEN CHRONIC DICOFOL EXPOSURE AND THE 
RISK OF ALZHEIMER’S DISEASE 
EOIN MORIARTY 
ABSTRACT 
 Alzheimer’s Disease (AD) is a disorder that causes progressive cognitive 
impairment. It’s a unique neurodegenerative disorder in which beta amyloid plaques and 
neurofibrillary tangles begin to preoccupy brain tissue. AD has been a historically 
difficult disease for society to examine partially because it’s etiology is still not well 
understood. One of the risk factors associated with AD development that has been 
researched is exposure to pesticides, primarily focused on the pesticide 
Dichlorodiphenyltrichloroethane (DDT).  
Studies have shown that DDT disrupts both the neurological and endocrine 
systems. As a result, this disruption leads to hyperexcitability of axons as well as a loss of 
neuroprotection thereby causing an increased susceptibility to Alzheimer’s Disease. 
Although DDT has been extensively studied, other pesticides are still used in large 
amounts throughout the world. One pesticide that’s particularly used to do it’s low cost 
and availability is Dicofol. Dicofol is a DDT derivative in which it’s structure is similar 
to the structure of DDT. Although Dicofol is similar to DDT in terms of structure and 
use, research into the effects of Dicofol exposure has not been extensively performed. 
The following study has been proposed in order to investigate a relationship between 
Dicofol exposure and the risk of developing AD.  
	
 vi	
The study performed is a retrospective cohort study of 1134 people consisting of 
pesticide applicators collected from the Agricultural Health Study. A licensed neurologist 
using the Mini Mental Status Exam will assess if cognitive impairment is present in the 
participants. Those that are believed to be cognitively impaired will then undergo 
neuroimaging to confirm the presence of beta amyloid plaques, which are indicative of 
AD. Finally a Chi Square analysis will be used in order to determine if there are 
associations between exposure status and AD diagnosis.  
 This study has both clinical and public health significance. As stated previously, 
dicofol is still used widely in many countries due to it’s availability and low cost. 
Therefore, many agricultural workers may be unknowingly exposing themselves to a 
pesticide that can increase their susceptibility to neurodegenerative disease. This concern 
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Alzheimer’s disease (AD) affects approximately 5.5 million people, most of 
whom are older than 65. AD is a neurodegenerative disease that affects short-term 
memory, cognition, speech, and the ability to perform daily activities. It’s a devasting 
disease that causes families to watch their loved ones gradually disappear.  
Since it was first discovered, researchers have been investigating the genetic 
susceptibility of the disease, the underlying pathology, the progression of cognitive 
decline, the loss of capacity as the disorder develops and AD related risk factors, such as 
head injuries, lower education, and exposures to environmental toxicants.  
Statement of the Problem 
One risk factor that appears to be associated with AD is the exposure to 
pesticides.  Dichlorodiphenyltrichloroethane (DDT), for example, has been associated 
with developing neurodegenerative diseases later in life.1 Further, research has found 
DDT disrupts both the nervous and endocrine systems.2 Studies have reported calcium 
channel gates in neurons stay constantly open following DDT exposure, leading to hyper-
excitability and resulting in synaptic disruption. It’s been hypothesized that this synaptic 
disruption could cause neurodegeneration, leading to AD. It has also been reported that 
DDT affects estrogen receptors, resulting in an increase in estrogenic response. Although 
estrogen is known to be neuroprotective, an increase in the estrogenic response could 
result in a negative feedback loop, causing an overall decrease in estrogen and, 
ultimately, decreasing estrogen-related neuroprotection.3 This decrease in 
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neuroprotection then causes an increased risk of developing AD.4 It’s been hypothesized 
that this decrease in estrogen-related neuroprotection then causes an increased risk of 
developing AD.5 Although DDT was a useful pesticide and lowered the risk of malaria in 
the United States, it was banned in the 1970s because the health and environmental risks 
were too high. However, despite this ban, alternative pesticides such as dicofol were still 
being used before being banned. Dicofol’s chemical structure differs from DDT in that it 
has an additional hydroxyl functional group on C-1. While there’s evidence on early 
DDT exposure and developing neurodegenerative disorders, such as AD, very little is 
known about whether exposure to chemicals similar to DDT, such as Dicofol, puts an 
individual at greater risk of developing AD. 
Hypothesis 
Long term dicofol exposure will be associated with an increased risk of developing 
Alzheimer’s disease.  
Objectives and specific aims 
Objective: To find a positive association between dicofol exposure and an increased risk 
of Alzheimer’s Disease. Specifically, this study aims to: 
 
• Recruit a cohort of subjects who were previously exposed to dicofol and are now 
old enough to develop AD and a control group of similar age, location, and 
education status who were never exposed to dicofol. 




• To assess each cohort for Alzheimer’s disease by examining them in a physical, 
neurological and psychiatric exam as well as a Modified Mini Mental State (3ms) 
exam 
• Examine an association between long term dicofol exposure and an increased risk 




REVIEW OF THE LITERATURE 
Overview 
Alzheimer’s disease (AD) is a neurodegenerative disorder that occurs most commonly in 
those over the age of 60. According to the National Institute on Aging, more than 5.5 
million people in the United States over the age of 65 may have AD-related dementia. 
There are more than 700,000 AD-related deaths in the United States yearly.6 The average 
time from diagnosis to death is 8 years, however those suffering from the disease can live 
20 or more years after diagnosis. AD-related dementia is characterized by cognitive 
decline with early deficits in short-term memory, language, and executive functioning. 
Although patients have trouble remembering recent events and information, their older 
memories remain in the initial stages of the disorder until eventually they lose their long-
term memory. AD patients have word-finding difficulty and have trouble expressing their 
emotions. In addition, AD dementia produces significant problems with planning, multi-
tasking, organizing, making decisions, or insight into the fact that they have a 
neurodegenerative disease.  
AD is classified into different categories based on severity. Mild dementia involves some 
neurological impairment, such as short-term memory loss, however the patient can still 
function independently. With moderate dementia, the patient shows dependence in many 
areas but is independent in self-care. In severe dementia, the patient requires assistance in 
all basic activities, including using the restroom, grooming and dressing. Alzheimer’s 
dementia also affects the caregivers who devote their time and emotions to caring for the 




Alzheimer’s Disease Pathophysiology 
Neuritic plaques are formed when amyloid protein undergoes incorrect enzymatic 
cleavage of the Amyloid Precursor Protein (APP), resulting in a fibrillar form of amyloid 
protein known as beta-amyloid.8 In comparison, neurofibrillary tangles are formed when 
the microtubule associated protein tau becomes hyperphosphorylated, misfolds and 
begins to aggregate with other mis-folded tau proteins resulting in the neurofibrillary 
tangles.  
Although plaques and tangles are hallmark characteristics of Alzheimer’s disease, 
they do not form immediately. Rather they progress insidiously for years before a 
diagnosis is made. The progression of Alzheimer’s disease begins with accumulation of 
beta-amyloid plaques years to decades before symptoms occur, resulting in synaptic 
dysfunction7. Tau proteins then begin to misfold, leading to injury within the neurons. 
The injured neurons then begin to atrophy and symptoms begin to arise, progressively 
leading to dementia. 
 
Organ System disruptions related to Alzheimer’s Disease  
In addition to the biomolecular changes that lead to Alzheimer’s disease, 
disruptions in other organ systems may lead to an increased risk of susceptibility. For 
example, disruptions in the endocrine system, specifically changes in estrogen levels, 
have been found to be associated with an increased risk of Alzheimer’s disease. Estrogen 
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is a sex hormone produced in the follicles of ovaries and the corpus luteum/placenta.9 
Estrogen is also produced in smaller amounts in the liver and adrenal glands. Estrogen 
receptors (ER) are highly populated in the brain. For example, ER-alpha is located 
mainly in the hippocampus and ER-beta is located in the forebrain and cerebral cortex. 
Studies have shown that estrogen is beneficial in the protection of brain tissue, however, 
the mechanism has not been fully explained. Estrogen promotes the growth and survival 
of cholinergic neurons, increases cholinergic activity, has antioxidant properties, and 
promotes the metabolism of APP. APP is a precursor protein of beta-amyloid, the main 
component of amyloid plaques in AD. As a result, it is strongly suggestive that a decrease 
in estrogen results in a decrease in neuroprotection, thereby, increasing the risk of 
developing AD in the future.  
 
Genetic Determinants 
There are two different types of Alzheimer’s disease, familial and sporadic. 
Familial Alzheimer’s Disease is rare (approximately <1% of Alzheimer’s Disease) and 
usually occurs within families due to dominant mutations in the genes Presenillin 1, 
Presenillin 2, and APP. Sporadic Alzheimer’s disease is more common. There is no 
single causative gene for the disease but mutations in the Apolipoprotein (ApoE) gene 
can increase the risk of developing the disease. The ApoE gene is responsible for a 
protein that helps form lipoproteins. Lipoproteins are essential in packaging molecules, 
including estrogen, for transport throughout the body.11 There are three alleles of the 
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ApoE gene: ε2, ε3, ε4. Those with the ε2 allele are more likely to develop Alzheimer’s 
disease dementia later in life in comparison to those with the ε4 allele. The ε3 allele is the 
most common allele on the ApoE gene and is believed to have a neutral role in 
Alzheimer’s disease dementia while the ε4 allele increases ones risk in developing AD 
with an earlier age of onset.  
 
Gender  
In addition to genetics, there is an increased risk of developing AD in women. 
Women have a 1/6 chance of developing AD in their lifetime compared to men who have 
a 1/10 chance.12 More than half of the AD population in the U.S. are women. It is 
possible that women have an extended period of time in which they can develop the 
disease as they generally live longer than men and AD is an age-related disease. Thus, 
women may be more likely to develop Alzheimer’s disease. However, the longevity of 
women is not the only reasoning behind their increased susceptibility to AD. Women 
with the ApoE-4 gene variant were found to have an even more substantially increased 








The diagnosis of Alzheimer’s disease has improved immensely since it was first 
discovered, primarily due to an increased knowledge of the clinical manifestations and 
the biology underlying the disease. The original criteria for AD diagnosis required 
extensive revision including that the histological changes associated with AD can be seen 
in people who are cognitively normal. In addition, the presence of Lewy bodies, vascular 
dementia, behavior variant fronto-temporal dementia, and primary progressive dementia 
were all omitted in the criteria due to the fact that these disorders could not be recognized 
when AD was first discovered14. There were also no CT, MRI, or PET imaging or CSF 
assays when AD was first discovered. Also noted in the original Alzheimer’s disease 
criteria, memory impairment was the primary cognitive deficit and this has since been 
redacted. It is now understood that symptoms such as posterior cortical atrophy and 
primary progressive aphasia can occur before memory impairment. The genetics of AD, 
specifically APP, presenilin 1 and presinilin 2 gene mutations, were also not included in 
the original criteria. Therefore, it was evident that new criteria were needed for the 
evaluation and diagnosis of AD.  
The National Institute of Aging notes that AD is ultimately diagnosed by 
examining the brain tissue in an autopsy, or biopsy in some cases, for areas of atrophy 
primarily near the hippocampus and the frontal temporal lobes. Physicians diagnose 
Alzheimer’s disease by asking family members questions about the patient such as the 
status of their overall healthy, what prescriptions they have, any past medical problems, 
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any difficulty pursuing daily activities, or any changes in behavior or personality. 
Clinicians may also perform memory, problem solving, attention, or counting tests, as 
well as blood and urine screens, to exclude any other reasons for the current symptoms. 
Finally, physicians may diagnose their patients through brain scans. CT, MRI, and PET 
scans can be administered in order to assess for AD or exclude other possible causes for 
the patient’s symptoms.  
 
Comparing Imaging Modalities 
When using an MRI to assess for AD, two factors can be detected.15 First, atrophy 
can be assessed, as well as changes in the tissue that would cause visualized vascular 
damage as white matter hyperintensities in T2-weighted images. In terms of atrophy, the 
typical pattern that is seen in AD begins with the entorhinal cortex, followed by the 
hippocampus, amygdala, and parahippocampus. Because increased cerebral atrophy 
occurs early in the disease in severely affected individuals, MRI imaging can be a marker 
of disease progression and used as a potential outcome measure in trials. The main 
benefit of using an MRI is its availability. Both US and European guidelines recommend 
structural imaging such as MRI for the diagnosis of Alzheimer’s, as well as other forms 
of dementias. The benefit of MRI in comparison to CT is that MRI does not require 
exposure to ionizing radiation, eliminating the risk of carcinogenecity. Because an MRI 
can measure atrophy, it can reflect cumulative neuronal damage and, therefore, is one of 
the more beneficial modalities of imaging when assessing and diagnosing AD. It should 
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be noted, however, that although atrophy is strongly correlated with cognitive decline, 
patterns of atrophy overlap with other diseases that are separate from AD. Additionally, 
MRI is limited in that it cannot detect the histopathological changes associated with AD, 
such as amyloid plaques or neurofibrillary tangles. 
PET imaging in AD is generally used to identify synaptic activity. The brain relies 
exclusively on glucose as its source of energy. Therefore, using the glucose analog 
fludeoxyglucose (FDG) in a PET scan, one can appropriately evaluate brain metabolism 
when it is labeled with Fluorine-18. The resting activity of the brain requires the most 
energy, in which the highest amount of glutamaturgic synaptic signaling is found in the 
cortex. FDG uptake is strongly correlated with synaptic activity and, therefore, PET scans 
using FDG are widely accepted as a bio-marker for brain metabolism. In AD patients, 
hypometabolism characteristically occurs in the limbic and associated regions of the 
brain. AD patients have visibly low synaptic activity in certain regions under PET 
including: the posterior midline cortices of the parietal and posterior cingulate gyri, the 
inferior parietal lobule, the posterolateral portions of the temporal lobe, the hippocampus 
and the medial temporal cortices. Throughout course of AD, the metabolism of the brain 
decreases and bilateral asymmetry is commonly seen early on PET scans.  
Once AD is established, deposition of amyloid plateaus but, along with cognitive 
function, FDG uptake continues to decline. High amyloid deposition in the parietal 
regions was found to be associated with FDG hypometabolism, which raises the 
possibility of local toxicity. This relationship between high amyloid deposition in the 
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parietal regions and FDG hypometabolism may be inaccurate, however. Studies have 
found this association to not be significant primarily because the amyloid burden seen in 
the subjects were already plateaued. In addition, this relationship was found to be weaker 
in the frontal regions of the brain in which the highest amount of amyloid is found. 
Additional research is needed to further investigate the relationship but FDG metabolism 
appears to change with amyloid build-up. In fact, this may illustrate an intermediate stage 
between the beginning of pathological changes and the development of degeneration, as 
well as synapse disruption.  
FDG PET scans have become a popular marker of neurologic dysfunction in AD. 
FDG PET scans are valuable in two instances: when confounding incidences, such as 
frontotemporal lobar degeneration (FTLD) occur, FDG PET scans can alter an 
ambiguous AD diagnosis to a FTLD diagnosis; and when hypometabolism occurs prior to 
the presence of cognitive changes, FDG PET can predict the rate at which cognition 
decreases in the future. FDG PET scans are clearly beneficial, however, the limitations of 
these scans are largely due to their price and limited availability. In addition, these scans 
are further limited because they require IV access and expose patients to radioactivity 
despite it being low-risk. 
Amyloid PET scans are used to reflect beta-amyloid pathology but do not reflect a 
clinical diagnosis. The substrate for all known beta-amyloid tracers is fibrillar beta-
amyloid specifically in the beta-sheet confirmation. When discussing beta-amyloids, it’s 
important to differentiate between fibrillar and nonfibrillar forms and to avoid using 
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terms based on visual descriptions due to the differing amount of beta-amyloid seen in 
the visually descriptive plaques. Visually descriptive plaques such as compact, cored, and 
neuritic plaques have larger amounts of amyloid compared to fleecy and amorphous 
plaques. There may be an association between the amount of signal in an amyloid PET 
scan and the concentration of amyloid oligomers. The amyloid PET scan is beneficial 




Figure 1: PiB PET image of AD subject showing heavy beta-amyloid deposition15.  
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Beta-amyloid PET scans are extremely useful in diagnostics. A study performed 
by Johnson et. al in 2012 found that, in 17 research groups groups in which an amyloid 
PET scan was performed on clinically diagnosed AD patients, 96% were found to be 
positive for a heavy amyloid burden using the diagnostic criteria as the gold standard.15 
Thus, those 4% of amyloid-negative patients may have been misdiagnosed as having AD. 
Alternatively, the scans may not have been sensitive enough and eventually the patients 
who were amyloid-negative would become positive over time. However, follow-up of the 
amyloid-negative subjects found that none became positive over 5 years and, therefore, 
sensitivity was not the cause for the scans providing amyloid-negative results. 
Additionally, in the case of diseases similar to AD such as MCI, nine studies provide 
results in which MCI patients were scanned and found to be amyloid positive. Given that, 
it’s apparent that the most prevalent use of amyloid PET scans would be in elderly 
patients that have normal cognitive function in which cerebral beta-amyloidosis could be 
detected in the “invisible stage.” By discovering cerebral beta-amyloidosis in 
asymptomatic patients, it allows more opportunity for providing treatment. Similar to the 
FDG PET scan, the major limitation of amyloid PET scans are pricing and availability. 
When comparing the amyloid PET scan to other imaging modalities such as an MRI or 
FDG PET, it provides a definitive diagnosis in which it can clearly show that beta-
amyloid is present, in comparison to MRI and FDG PET scans which are not as specific.  
In addition to amyloid PET scans, cerebral spinal fluid (CSF) biomarkers can be 
used in AD diagnosis. Decreases in beta-amyloid in CSF occurs as early as, if not earlier 
than, changes seen in the amyloid PET scan and in those that are pre-symptomatic. 
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Differences in amyloid levels in CSF and using a PET scan appear to be insignificant, as 
they both appear useful in assessing for beta-amyloid accumulation. CSF measurements 
are advantageous in comparison to amyloid PET scans because they are not as expensive 
and can provide similar information on whether or not beta-amyloid is accumulating 
within the brain. However, because amyloid PET scans are more dynamic and correlate 
directly with beta-amyloid load, they appear to be the superior method. In addition, a 
major limitation to assessing amyloid levels in CSF is that the levels are correlated 
strongly to only brain regions adjacent to CSF spaces compared to amyloid PET scans 
which cover all brain regions. However, if one needs to only determine the presence of 
beta-amyloid within the brain, measuring levels using CSF can be more cost efficient.  
 
Assessment  
In order for a patient to be diagnosed with Alzheimer’s disease, their cognitive 
function must be assessed using formal testing protocols such as the Montreal Cognitive 
Assessment (MoCA) or detailed neuropsychological testing. Screening protocols such as 
the MoCA examine a patient’s orientation, attention and working memory, episodic 
memory, language, spatial awareness, and executive function (Figure 2). A MoCA score 
<26 suggests cognitive impairment in many patients. In some patients, especially those 
who are cognitively high functioning, scores above 26 can occur when the patient has 
diagnosable AD. In these cases, more detailed neuropsychological assessment is 
necessary to determine whether cognitive impairments exist. Once the patient is 
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determined to be cognitively impaired, reversible causes of cognitive impairment, 
including B12 or folate deficiency, thyroid dysfunction, depression, and medication side 




Figure 2: MoCA test courtesy of mocatest.org 
 
In addition to assessing cognitive function, patients with suspected Alzheimer’s 
disease must be assessed for functional independence. Often the Functional Activities 
Questionnaire is used.16 The questionnaire contains 10 questions that determine whether 
the patient can perform various daily tasks, such as paying bills, shopping, organizing 
their home, and understanding current events. Each question is scored from 0 to 3. A 
score of 0 indicates that the patient has difficulty performing the action but can do it by 
themselves. A score of 1 indicates that the patient requires assistance to perform the task. 
A score of 3 indicates that the patient is completely dependent on someone to assist them. 
Any total score greater than or equal to 9 qualifies the patient as impaired. 
 
Treatment 
There are four current medications for treating those diagnosed with Alzheimer’s 
disease:17 Donepezil, Galantamine, Rivastigmine, and Memantine. These medications, 
however, provide only symptomatic relief for a limited duration and are not curative17. 
Cholinesterase inhibitors such as Donepizil, Galantamine, and Rivastigmine prevent the 
breakdown of acetylcholine, a neurotransmitter which is involved with functional 
learning and memory. These medications are generally administered with Memantine, an 
N-Methyl-D-aspartic acid (NMDA) receptor antagonist, which blocks the toxic effects 
associated with excess glutamate often found with cholinesterase inhibitor use. NMDA 
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receptor antagonists regulate glutamate, thereby reducing the chance of a chronic increase 
in calcium, which has been associated with neuronal injury.  
In addition to medication, Alzheimer’s disease patients are also advised to make 
lifestyle changes in order to reduce the progression of the disease. These lifestyle changes 
include increasing cardiovascular exercise, maintaining a Mediterranean diet, and trying 
various new complex projects to stimulate cognitive function.  
 
Pesticides related to Alzheimer’s disease 
AD does have a genetic susceptibility seen with familial Alzheimer’s, however, 
these cases make up <1% of the diseases’ incidence. The majority of Alzheimer’s disease 
cases occur sporadically or because of exposures or other events occurring during the 
patient’s lifetime. A possible cause includes exposures to certain neurotoxicants 
throughout their lifetime. An important example of these neurotoxicants are 
Dichlorodiphenyltrichloroethane and dicofol.  
Dichlorodiphenyltrichloroethane (DDT) is a pesticide first used on crops in the 
United States during the 1940s around World War II, in order to reduce the incidence of 
malaria and typhus in the United States. Before it was banned, DDT was one of the most 
popular pesticide due to its low cost and effectiveness. Approximately 1,350,000 pounds 
of DDT was used before it was banned, according to the Environmental Protection 
Agency.18 DDT belongs to a group of pesticides, organochlorines, that have very low 
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solubility in water and very high fat solubility, thereby increasing resistance to 
degradation while allowing the insecticide to move freely through the axonal membrane. 
The active structure of DDT involves phenyl rings connected by a mono-substituted 
methylene bridge ensuring stability in its active state.  
DDT’s mechanism of action on insects involves preventing axonal sodium gates 
from closing when the axonal membrane has been depolarized in the peripheral nervous 
system. As a result, an excess of sodium ions flows through the axon and causes 
hyperexcitability throughout the axon, leading to neurotoxicity. Because axons are 
hyperexcited in the setting of DDT exposure, common symptoms seen with DDT toxicity 
are body tremors, vomiting, and convulsions. According to the National Pesticide 
Information Center, DDT is broken down within the body into less toxic metabolites, 
such as DDD, DDE, and DDA. These metabolites are slowly excreted through urine, 
feces, or breast milk. In the setting of starvation, DDT can be released from fat stores into 
the circulatory system, causing hepatotoxicity and neurotoxicity.19 
According to the National Pesticide Information Center, DDT is moderately toxic 
to animals and humans; the LC50 for inhalation is between 0.2-2 mg/L. DDT exposure 
can be measured in blood or fat. The soil half-life of DDT can range between 2-15 years 
and as long as 150 years in an aquatic environment, thus making it very dangerous and 
persistent for aquatic wildlife. Because of its long half-life and availability to be built up 
in aquatic environments, fish began to accumulate amounts of DDT. Those fish were then 
eaten by predators who accumulated larger amounts of DDT until the primary predator 
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received the highest dose, therefore resulting in biomagnification. Eventually, due to the 
environmental and wildlife repercussions caused by DDT use, the EPA banned the 
substance in the United States in 1972.   
Although DDT is banned in the United States, it is still considered a cost-efficient 
pesticide in lower income countries, such as those in Africa, South America, and Asia, 
which continue to use it to reduce the risk of malaria. In addition, contamination of soil 
and water in the U.S. through long-term DDT use have resulted in chronic exposure to 
the population despite the fact that it is no longer actively used. In terms of occupational 
hazards, farmers are considered to be those with the highest risk of exposure, thereby 
making them more susceptible to chronic diseases possibility associated with exposure, 
such as AD.20  
DDT not only affects the nervous system; the organochlorine can also affect the 
endocrine and reproductive systems. Microvesicles, such as those containing DNA, RNA, 
lipids, and transcriptional factors, are used in communication between cells. DDT 
disrupts the thyroid by preventing the Thyroid Stimulating Hormone (TSH) receptor from 
attaching to the raft containing compartments of cells21; the TSH receptor is prevented 
from activating and becoming internalized. In addition, DDT can induce the formation of 
extracellular viscose that contains the TSH receptor and autoimmune responses against 
the receptor can develop, leading to Grave’s disease. Although this appears unrelated to 
AD or neurodegenerative disorders, it is important to acknowledge the effects that 
pesticides can have on organ systems throughout the body.  
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Another study pertaining to the effects of pesticides on other organ systems 
includes a study performed by Jaga et. al investigating DDT’s effects on estrogen 
receptors in the reproductive system22. The researchers note that because estrogen is more 
studied in females, they limited their scope to investigating DDT’s relationship to breast 
tissue and the uterus. The researchers used an E-SCREEN assay on MCF-7 cells to 
measure proliferation of epithelial cells found in breast in uterine tissue. DDT was found 
to cause an estrogenic response in those exposed; DDT induced the formation of 16-
alpha-hydroxyesterone, a derivative of estrogen, which has been found to be more 
estrogenic and genotoxic. These findings are important because a higher ratio between 
16-alpha-hydroxyesterone and 2-hydroxyesterone has been found to be a risk factor for 
breast cancer. O,p’-DDT, a metabolite, competes with estrogen to bind the estrogen 
receptor (ER). A second mechanism could hypothetically cause a synergism between 
DDT and estrogen, allowing the substances to bind to two separate sites on the same ER 
and, thereby, enhancing the estrogenic response.  
Dicofol is an organochlorine derived from DDT. Dicofol was developed in 1986 
as an acaricide and used on a variety of produce and crops. The EPA temporarily banned 
dicofol in 1990 due to concerns that there was DDT contamination when processed.23 
Presently, dicofol is manufactured carefully to ensure that it contains less than 0.1% 
DDT. The structure of the acaricide is very similar to DDT, however, it has a hydroxyl 
functional group on C-1 in comparison to the hydrogen at that positione on DDT (Figure 
3). Dicofol’s mechanism of action is unclear, however, it is speculated to involve 
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overstimulation of peripheral nerves and previous studies have noted an association of the 
pesticide with endocrine system disruption.  
 
 
Figure 3: Chemical structures of o,p’-substituted DDT (left) and dicofol (right) (CAS No. 
789-02-6 and 10606-49-9, respectively). Chiral carbon atom denoted by ‘‘*”. Courtesy of 
Hoekstra et al, 2006 
 
Similar to DDT, dicofol is stored within fat and is excreted through feces. The 
LC50 of dicofol in rats was noted to be >5mg/l for 4 hours.24 Dicofol is considered to be 
moderately toxic to humans, causing symptoms ranging from nausea and vomiting to 
fatigue with respiratory exposure to severe cases of convulsions and death from 
respiratory failure. The WHO reported that the soil half-life of dicofol is approximately 
60 days. However, it is very persistent in water, thereby making aquatic wildlife 
susceptible to toxicity. In addition, dichlorobenzophenone (DCBP), a degradation product 
of dicofol, has also been attributed to its toxicity. DCBP is similar to the DDT metabolite 
DDE and works similarly to DDE; they have both exhibited antiandrogenic properties in 
African green monkey kidney cells (COS-7) and in human mammary carncinoma cells 
(T47D).25 Therefore, if dicofol and DCBP both have antiandrogenergic properties, they 
could potentially reduce the amount of estrogen in the body and, thereby, reduce 
	
22 
neuroprotection in the nervous system. This decrease in neuroprotection could result in 
an increased risk for developing Alzheimer’s disease.  
Existing research 
 The relationship between organochlorine pesticides, such as DDT, and nervous 
system function has been examined extensively. Multiple studies have found that long-
term exposure to DDT increases the risk of developing neurodegenerative disorders, 
including AD. However, very little is known about pesticides similar to DDT. Dicofol 
was used worldwide after DDT was banned because it was thought to be a non-toxic 
replacement. However, very little is known about a possible relationship between dicofol 
exposure and risk for developing AD. Because dicofol may affect the endocrine system in 
ways that are similar to DDT, it may also damage the nervous system years after 
exposure. Therefore, investigation into the association between long-term exposure to 
dicofol in populations, such as agricultural workers or pesticide sprayers, and their risk of 
developing AD is warranted. It should also be noted that unfortunately in most of the 
studies listed, most sprayers sprayed multiple pesticides thereby causing it to be very 
difficulty to identify each pesticide’s individual contribution.   
  
Acute Neurologic Effects of DDT exposure  
Although DDT was banned in the U.S. during the early 1970s, countries 
continued to use the pesticide because they felt that the benefits in malaria control 
outweighed the environmental and health risks. Misra et al, examined the effects of DDT 
exposure on the cognitive functions of agricultural workers in India who continued to use 
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the substance despite it being banned in higher economic countries.26 Workers who 
sprayed DDT on crops for at least a year and had sprayed DDT at least a week before 
testing (N=29) were recruited for the study. Each subject recorded a detailed history of 
their diet and drug intake to rule out any extrinsic factors that would negatively affect 
nervous system function. They underwent a physical, neurological, and psychiatric exam. 
The intellectual capacity of each subject was determined using a combination of the 
Koh’s block design test, the Passalong test, immediate memory tests, picture completion 
and pattern-drawing test, memory function tests, and Bender Gestalt Test (BGT) visual 
motor exam. This combination of assessments was known as the Bhatia battery 
performance test. Nine of the subjects who had an abnormal Bender Gestalt score 
underwent an electroencephalogram (EEG). To measure DDT exposure, serum samples 
were obtained from each of the 17 sprayers and 12 controls and assessed using gas liquid 
chromatography for a total of 29 subjects. Any subject with evidence of malnutrition was 
excluded from the study. In addition to these 29 workers who sprayed 5% DDT year-
round without the use of protective equipment or face masks, the investigators identified 
26 healthy individuals who had not been exposed to pesticides for controls and were 
matched based on age, sex, and socioeconomic status.  
The exposed group had an average age of 39.3 years and were exposed to DDT on 
average for 12.7 years. Despite the chronic exposure, those that sprayed DDT considered 
themselves healthy with mild cognitive symptoms that didn’t interfere with daily 
activities. Within the exposed group, 27.5% reported psychological symptoms, such as 
irritability, anxiety, forgetfulness, and depression, and 10.3% reported worsening 
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symptoms following spraying. Additionally, 24% of exposed workers noted that they had 
“soft” neurological signs, such as hyperactivity of deep tendon reflexes, tremors, 
fasiculations, and loss of reflexes.  
Those that sprayed DDT had higher BGT scores than the controls in both age 
categories (P<0.1 below 40 years, P<0.05 above 40 years, mean serum DDT in 
sprayers=0.212 ppm and in controls 0.007 ppm, BGT scores in sprayers below 40 
years=58.54, BGT scores in controls below 40 years=38.50, BGT scores in sprayers 
above 40 years=64.56, BGT scores in sprayers below 40 years=40.50). Of the nine 
workers with abnormal BGT scores, 55% showed significant EEG changes, including 
decrease in alpha activity, low voltage record, asymmetry. Serum DDT levels in the 
exposed group showed a definitive correlation with the duration of exposure (r=0.32, 
8.5x higher levels DDT compared to controls) but there was a higher correlation found 
between BGT scores and DDT levels (r=0.46).  
This study is informative as it was one of the first to assess effects of occupational 
exposure to DDT. The study does have limitations, however. Because of the small sample 
size (n=29) and the recruitment of only male subjects leads to the question of the effects 
of DDT exposure on women and, thereby, revealing the need for more research with a 
larger, diverse study population. A small sample size in this study is an issue because it 
increases the risk of a Type II error. In addition, the study notes that the subjects were 
exposed to other pesticides besides DDT such as BHC and Malathion in small quantities. 
Even though the study notes the exposures were in small quantities, it could potentially 
skew the results of the study. It should also be noted that the study does not investigate 
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DDT-related pesticides or DDT analogues, such as dicofol, thereby requiring further 
research into their association with neurological effects. 
 
Chronic effects of DDT exposure on the nervous system 
Van Wendel et al. investigated the correlation between long-term exposure to 
DDT and nervous system outcomes in older populations.30 Because the researchers 
wished to study a population known to have long-term exposure to DDT, they recruited 
former malaria-control workers with known pesticide exposures in Costa Rica and 
assessed CNS function utilizing their neurobehavioral outcomes. They hypothesized that, 
in comparison to a control group, those exposed to DDT for a long period of time would 
have a significantly worse neurobehavioral performance.  
The register of the Ministry of Health in Costa Rica was used to recruit 59 retired 
men ranging in age from 55-70 who had been exposed to DDT between 1955 and 1996. 
Only those that had been exposed to DDT for a minimum of 2 years prior to the study 
were included. The control group was comprised of 64 male retired guards and drivers of 
similar age and educational attainment as the exposed group. Of those approached for 
consent, 36 men from the exposed group and 31 men from the control group agreed to 
participate in the study. Exclusion criteria for the case group included previous epilepsy 
diagnosis, cerebral hemorrhage diagnosis, prior diagnosis of intoxication of a 
cholinesterase-inhibiting pesticide or recent exposure to a pesticide. The study was 
unspecific as to how long since the subjects were exposed to the pesticide. Exclusion 
criteria for the control group included Parkinson’s disease diagnosis, childhood spastic 
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paralysis diagnosis, and previous DDT or cholinesterase inhibiting pesticide exposure. 
Each subject underwent clinical, neuropsychological, and psychiatric assessments. 
Neurobehavioral assessment outcomes (N=17) were used to assess their cognitive, motor, 
and sensory functions. In addition, the subjects were divided into high, medium, and low 
exposure subgroups. Odds ratios were calculated using multiple logistic regression and 
adjusted for potential confounders, such as age, history of loss of consciousness, visual 
acuity, and smoking habits.  
Participants with long-term DDT exposure performed more poorly than the 
control group (up to 20% decrease in mean performance for cognitive sequencing, trails-
A at 95% CI). In the high exposure subgroup, scores were significantly poorer on 
outcomes that assess visual-motor speed and verbal attention. In addition, the high 
exposed group reported significantly more neuropsychological and psychiatric symptoms 
than the control group (OR=3.98 CI at 95% 1.02-15.63). Therefore, the tests in cognitive, 
motor, and sensory domains show a significant exposure-effect relationship with DDT.  
This solidifies previous research on the effects of DDT on neurobehavior, while 
demonstrating that DDT has chronic, as well as acute effects on the nervous system. It is 
limited, however, similar to the previous study in that only men were selected for this 
study. The study also suffers a potential assembly bias as it did not detail specifically how 






Assessing Occupational Exposure and the risk of developing AD 
A recent meta-analysis published in January 2019 by Gunnar Gunnarsson et. al 
investigated a correlation between pesticide exposure and Alzheimer’s disease as well as 
other neurodegenerative diseases, such as Amyotrophic lateral sclerosis (ALS) and 
Parkinson’s disease.31 The researchers applied the Meta-analysis of Observational Studies 
in Epidemiology (MOOSE) and Grading of Recommendations, Assessment, 
Development and Evaluations (GRADE) guidelines to conduct a meta-analysis.  
The authors identified 31 studies that pooled indicated a 50% increased overall 
risk of developing AD, ALS and PD following pesticide exposure (weighted RR for AD 
= 1.50; 95% CI 0.98-2.29).  
The study was limited due to a potential publication bias and because they did not 
specify which pesticides each case had been exposed to, what dosage were they exposed 
to or the exposure length. These factors could influence the results, as some pesticides 
such as DDT are known to causes neurodegenerative changes, while others are known to 
be benign. Therefore, the results may be skewed depending on which pesticides the 
subjects were exposed to. In addition, the length and intensity of pesticide exposure could 
affect the risk of developing neurodegenerative disease. Therefore, by not distinguishing 
the length of exposure, the results could again be biased. It also did not specify which 
pesticides were related to development of specific neurodegenerative outcomes and is not 





The risk of AD in the setting of ApoE genotyping and pesticide exposure  
Richardson et al. (2004) conducted a case control study investigating the 
association between developing AD and elevated serum dichlorodiphenylethylene (DDE) 
levels, while also determining whether ApOE genotype modifies susceptibility to 
developing AD in this association.32 DDE is a metabolite of DDT that was used as a 
replacement for DDT in many countries. The researchers also aimed to investigate the 
relationship between DDT/DDE exposure and APP accumulation.  
Serum samples were obtained from Alzheimer’s Disease Research Centers at the 
University of Texas Southwestern Medical Center and Emory University. The samples 
were from control patients and patients with AD who were diagnosed in the centers 
between 2002 and 2008. Inclusion criteria for the control group consisted of a Mini -
mental Status Exam (MMSE) score between 28-30, no abnormalities in brain structure 
determined by MRI and/or a normal neurologic exam. AD cases met NIH and the 
Alzheimer’s Disease and Related Disorders Association criteria based on either their 
clinical exam results and MRI imaging or laboratory assessments that would rule out 
other medical causes for their dementia. Serum samples and genotyping were taken at 
enrollment when the MMSE was administered.  
In total, 79 controls and 86 AD samples were collected from prior studies and 
across the two sites, including 94 women and 71 men.  In order to determine the 
correlation between serum DDE levels and brain DDE levels, researchers obtained 11 
autopsy samples from patients who died at an average age of 85.7 years from the AD 
Center at Washington University. Before dying, these patients were diagnosed with AD 
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using the National Institute of Deurological and Communicative Disorder-Alzheimer’s 
Disease and Related Disorders association criteria with histological confirmation of AD 
via brain autopsy. Serum samples were collected approximately 193 days before death 
and the brain samples were collected 12 hours postmortem.  
The ApoE genotyping was determined using TaqMan PCR.  
Serum DDE levels were assessed using gas chromatography/mass spectrometry 
and were expressed in the context of free cholesterol levels with a detection limit of 
approximately 100 pg/mL. To determine the pesticide concentration in the collected brain 
tissue, 150mg of temporal cortex analytes were analyzed via gas chromatography/mass 
spectrometry.  
To investigate the association of APP levels with in vitro exposure to DDT/DDE, 
differentiated neuroblastoma cells (SH-SY5Y cells) were used. The cells were exposed to 
DDT or DDE for 48 hours, washed, and fixed in paraformaldehyde. The cells were then 
incubated using primary antibodies against APP and MAP2 and then fluorescently 
labeled with secondary antibodies. Microscopic images using a fluorescent illuminator 
were taken. The mean density/intensity (SEM) was then calculated 3 times.  
Unconditional logistic regression controlling for age, sex, and location controls 
was used to calculate the ORs and the 95% CIs for the association between serum DDE 
levels and AD diagnosis in both UTSW and Emory locations. To determine the 
probability of having AD and to evaluate a decrease in MMSE score per tertile of DDE 
level in a study population, while controlling for age, sex, race/ethnicity, education, 
APoE genotype and location, the researchers used generalized estimating equations. To 
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determine whether the ε4 allele of the ApoE genotype modified the association between 
DDE levels and MMSE scores, the researches stratified the data by genotype or used 
generalized estimating equations to create an interaction model. 
DDE concentrations were found in 70% of the control group and 80% of AD 
cases with a mean structural equal modeling (SEM) of 3.8x higher in the AD cases than 
in the control cases (2.64 ng/mL cholesterol, P<0.001). In the AD samples, no other 
organochlorine pesticide was found to be elevated besides DDE when compared to the 
controls. When neuronal cells were exposed to DDT or DDE for 48 hours, the APP levels 
increased by approximately 50% (confirmed using fluorescent microscopy at 20x 
magnification), indicating an accumulation in amyloid protein and supporting the theory 
that exposure to the pesticide leads to an increase in APP, a protein well known to be 
found in excess in AD patients on autopsy. In addition, the researchers found that the 
presence of the ApOE ε4 allele was not associated with an increased AD diagnosis (OR, 
3.70; 95% CI, 2.97-4.60; P < 0.0001) therefore they were unable to justify that the ApOE 
ε4 allele would modify the association between exposure and developing AD. In addition 
similar ORs were observed (OR, 3.60; 95% CI, 1.23-10.57; P < 0.001) when non detects 
were assigned to a value of zero.  
The relatively large sample size for this study and use of two locations 
geographically are strengths of this study. Because the levels of DDE mimic the levels 
found in the most recent National Health and Nutrition Examination Survey, the results 
are likely generalizable to the U.S. population. The study is limited, however, in that only 
organochlorine pesticides were investigated and in that it excludes other known harmful 
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pesticide exposures, such as organophosphates. In addition, the researchers note that 17 
of the 86 AD patients had levels of DDE that were undetectable, as well as control 
patients with extremely elevated DDE levels, therefore suggesting that DDE exposure 
may only be associated with AD progression in a certain number of cases or possibly due 
to unique genetics in certain individuals or other extrinsic factors.   
Their findings present a significant association between exposure to DDE and 
AD, as well as demonstrating that ApoE alleles did not modify the association in this 
study, it’s still a possibility that could be concluded with additional research. A possible 
underlying mechanism in the association between pesticide exposure and AD was 
identified, as APP levels were elevated when neuronal cells were acutely exposed to 
DDT and DDE. This research is important because, by determining a mechanism by 
which these pesticides can cause neuronal damage, treatment-involving inhibiting APP-
cleaving enzymes could be considered for workers who have occupational exposure to 
DDE, in order to inhibit the buildup of APP and reducing the risk of neuronal damage.  
 
Confirming the Association between DDT and AD 
 
The hypothesis that pesticide exposure earlier in life may lead to later 
development of neurodegenerative disease has received considerable attention. A review 
of the literature on this hypothesis was conducted by Yan et al. (2016) who hypothesized 
that pesticides such as DDT are related to an increased risk of developing Alzheimer’s 
disease due to their ability to cause mitochondrial and oxidative stress in neurons.33  
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In their systematic review, 1529 total articles were initially included, however, 
most were removed because they were either duplicates, not pertinent to the research, did 
not assess pesticide exposure, did not address AD as an outcome, or did not use a case 
control or cohort study design. The systematic review was narrowed to seven studies, 
four of which were case-control and three of which were cohort (Table 1). In total, 6,835 
participants were included in the seven studies, of which 1,050 were AD patients.  




Case Control Adjustments 
Tyas et al Cohort Subjects self 
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Hayden et al Cohort Subjects self 
reported either 
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Gun et al Case-control Respectively 
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French et al Case-control Respectively 
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factor 
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Table 1: Characteristics of the 7 studies used in the study by Yan et. al 
 
In their meta-analysis, the authors used a fixed-effects model to calculate 
summary ORs and 95% CI. They found the OR for the relationship between pesticide 
exposure and development of AD to be 1.34 (95% CI: 1.08-1.75) suggesting that there 
was a positive association. 
Pesticide exposure was associated with an increased risk of AD in all subgroup 
analyses, however, only half of the subgroups reached statistical significance. In the 
cohort studies, there was an increased odds of developing AD (OR=1.39, 95% CI=1.08, 
1.75) in comparison to no significant increased odds of developing AD seen in the case 
control studies (OR=1.24, 95% CI=0.78, 1.97).  
A strength of the study is that there appears to be no publication bias. An Egger’s 
test and Begg’s test was performed indicating no evidence of publication bias (Egger, 
P=0.66, Begg, P=0.81). However, the study also has many weaknesses in regards to bias. 
For example, because the patients with AD were selected from hospitals in the case-
control studies, there is the possibility of an admission rate bias that would need to be 
investigated further. Another weakness of the study is due to the fact that only select 
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cohort studies exhibited a positive association between pesticide exposure and AD risk, 
while case control studies failed to show any association. Therefore, because cohort 
studies are generally preferred in investigating etiological relationships, such as AD and 
pesticides, recall bias may be present. The design of the study causes limitations. The 
study includes incidence of AD in association with pesticide use rather than the 
prevalence of AD, therefore excluding ecological studies, which may help support their 
theory. Another limitation to the study was that the case-control studies had a much 
smaller sample size. The smaller sample size reduces the statistical power in comparison 
to the cohort studies. This lack of statistical power indicates a need for a new study with a 
larger sample sizes to confirm their results or a larger sample size with a more common 
exposure. The smaller sample size may have also contributed to the lack of significance 
noted previously. They also didn’t acknowledge which specific pesticides were being 
used as well as the length of exposure. In conclusion, a more extensive meta-analysis is 
warranted in the future due to the fact that a small number of identified studies were used 
(n=7).   
This study suggests a positive association between AD and exposure to pesticides 
at a low dose for long periods of time. The authors hypothesized that low dose long-term 
exposure to pesticides such as paraquat, dieldrin, organochlorines, and organophosphates 
is a risk factor for developing AD, however, they noted that a larger sample size is 
required to validate a causal relationship.  
 
Organochlorine Pesticides and decrease in cognition in the setting of the elderly 
	
36 
Because AD is largely a geriatric illness, a study performed by Kim et. al (2015) 
explored whether patients who had higher serum concentrations of organochlorines 
would have greater declines in cognition as they age than persons with lower exposures 
to organochlorines.34 They based this hypothesis on the known persistence of 
organochlorines in the body due to their lipophilic properties, as well as their ability to 
easily cross the blood-brain barrier. The researchers noted that despite OC pesticides 
being banned decades ago, their liphophilic properties allowed them to be stored in 
adipose tissue. Therefore, those who were exposed may have experienced either leaching 
of OC from their own fat stores or from eating the fatty meat of animals previously 
exposed to OC pesticide resulting in increased OC pesticide concentrations. 
Subjects were recruited using the National Health and Nutrition Examination 
Survey (NHANES), which measured serum OC levels in the 1999-2004 data collection 
and also their cognitive function aged 60-85 in the 1999-2002 data collection. The sample 
size of was 644. The Digit Symbol Substitution Test (DSST), a component of the 
Wechsler Adult Intelligence Test, was used to assess cognitive function. The DSST 
assesses visuospatial and motor speed-of-processing, has an executive function 
component, and is sensitive in measuring frontal lobe executive function. Patients were 
asked to draw symbols under a corresponding number in a period of 120 seconds with a 
max score of 133. Participants who were unable to complete the sample items did not 
continue testing.  
OC concentrations were measured using venous blood samples and gas 
chromatography, as well as mass spectrometry for quantification. Six OC pesticides were 
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chosen (DDT, DDE, beta-hexachlorocyclohexane, trans-nonachlor, oxychlordane, and 
heptachlor epoxide). Leach OC concentration was divided by the total lipid value for 
standardization.  
The DSST score and dichotomous DSST score (< 25% percentile) were used as 
study outcomes. The continuous measure represented the general populations DSST 
scores and the dichotomous reflected severe impairment. The first and second tertiles of 
pesticide exposure measure were combined to increase stability. Gender, race, ethnicity, 
level of education, income, smoking status, body mass index, presence of heart disease, 
diagnosed hypertension, and diagnosed diabetes were adjusted for in the study to prevent 
confounding. In addition, the results accounted for stratification and clustering in the 
NHANES to prevent any bias.  
A significantly lower DSST score was associated with aging and the difference 
between the lowest and highest age quintile DSST scores were approximately 16 symbols 
correctly substituted. An absolute low cognition score (DSST score <25% percentile, p 
<0.01) had a clear pattern of interaction with pesticide exposure, except in the cases 
involving DDT and DDE exposure.  However, both DDT and DDE had an increased 
prevalence of exposure in the lowest quartile DSST score in all age groups (p <0.01).  
The pesticides beta-heachlorocyclohexane, trans-nonachlor, oxychlordane, and 
hepatachlor epoxide were found to modify the association between age and cognitive 
function in the elderly population in the U.S. The association between increased age and 
lower DSST scores strengthened as OC pesticide concentration in serum increased. Other 
studies suggested that intrinsic and extrinsic factors, such as gender, education, ApoE, 
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physical activity, or food intake, alter the decline in cognition with aging but these 
previous studies had not investigated the role of OC pesticides in that association. The 
interactions of DDT and DDE with age were not significant but were associated with a 
lower DSST score in all age groups suggesting that DDT’s effect on cognitive function 
does not involve age.  
The study was limited because length of OC exposure was not included, thereby 
preventing the study from separately exploring the association of acute and chronic OC 
exposure with DSST scores.  Secondly, because the study was cross-sectional, attributing 
causality is difficult and, therefore, a prospective study would be more appropriate. 
Cognitive function was only evaluated using the DSST, thereby limiting the outcomes 
and revealing a need for a collection of tests to expand on other areas of cognition.  
 
Dicofol’s effect on the Endocrine System 
Previous research had hypothesized that DDT and DDT-related pesticides, such 
as dicofol, affect estrogen levels. Zhuang et al (2012) investigated the differences in 
conformational changes between the estrogen receptors when bound with DDT analogs, 
whether these differences result in different physiological responses, and what molecular 
moiety of DDT and its analogs favor binding to the receptors35.  
The researchers performed twelve molecular docking (MD) simulations using the 
DDT analogues with human ERα and ERγ ligand binding domains (LBD) and the 
conformational changes of each LBD was studied. The structures of DDT and its analogs 
with the ERs were modeled using MD methods taken from X-ray crystal structures 
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provided by the Cambridge Crystallographic Data Centre. Each algorithm was performed 
10 times. The structures of ERα and ERγ LBDs when in complex with DDT and its 
analogs were optimized using a MolProbity server.  
In terms of analyzing the binding of each compound to an ER, they were able to 
simulate 4,500 conformations of ERα LBD and 5,000 ERγ LBD. After evaluating for 
structural stability of hydrogen bond formation, the investigators discovered that 
aromatic-aromatic stacking was occurring and proposed that it helped stabilize the 
molecules. In addition, the binding affinities for each pesticide with the ERs were 
increased.  
They were able to observe the structural changes of DDT analogs when they bind 
to ERs resulting in different moieties such as the aromatic ring stacking resulting in an 
increase in both binding and affinities. It was suggested that because these pesticides are 
able to increase their binding and affinity to estrogen receptors, they are more likely to 
illicit endocrine disruption. Therefore, because DDT analogs could bind to ER in 
aromatic ring stacking, endocrine disruption would occur. 
 
Research of dicofol on the nervous system 
Unfortunately, the research on dicofol and its effects on the nervous system post-
exposure is very minimal. When using PubMed.org, there were no articles found 
investigating dicofol and its effects on the nervous system.  
Many studies listed above investigated different aspects of pesticide exposure and 
neurodegenerative disease. Researchers have investigated the acute and chronic 
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neurologic effects of DDT exposure, the risk of developing AD with occupational 
exposure, the risk of developing AD with pesticide exposure and a genetic predisposition, 
as well as the association between organochlorine pesticides and decrease in cognitive 
function.  Although these studies are beneficial, they mainly focus on DDT in terms of 
pesticide exposure. The research on an association between DDT derivatives such as 
dicofol and the development of AD is scarce. Therefore, a proposed study in which those 
who were exposed to dicofol for an extensive period of time in the past should be 
conducted to determine exposures and investigate relationships between exposure 














Chapter 3: METHODS 
Study design 
A retrospective cohort study of 1134 people consisting of pesticide applicators 
and their spouses will investigate associations between Dicofol exposure and risk of 
developing AD. The retrospective cohort design has two advantages: it allows an 
efficient means of examining an outcome that develops slowly over years and is effective 
for identifying rare exposures, such as Dicofol.  
Study population and sampling 
The study will sample participants aged 65 and older (probable age range 65-85) 
in the Agricultural Health Study (AHS), assembled in 1993-1997. Pesticide applicators 
from Iowa and North Carolina (N=57,310) were enrolled when they received or renewed 
their pesticide-use licenses, of whom 84% of eligible applicators completed an 
enrollment questionnaire.38 Enrollees were sent home with an additional questionnaire to 
enroll their spouses with 32, 345 (75% of those where were eligible) enrolling in the 
AHS.  
Inclusion criteria for this study include those that are currently >65 years old (per 
questionnaire data obtained at enrollment). Exclusion criteria include: history of head 
trauma, ischemic/hemorrhagic stroke, or medical record confirmation of diagnosis of any 
other neurodegenerative diseases (e.g., Parkinson’s disease, Lewy Body Dementia, 
vascular dementia, or epilepsy).  
A sample size of 1134 participants (n=567 in the exposed and non-exposed 
groups) is required to adequately power the study. This was calculated assuming an α of 
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0.05, a β of 0.2, a 1:1 recruitment of exposed to unexposed, risk of developing 
Alzheimer’s in the unexposed group of 0.13 (calculated risk of developing AD over the 
age of 65 as supported in a study performed by Brookmeyer et. al, 2011) and an OR of 
1.6 (calculated in a study performed by Kamel et. al, 2012 for another neurological 
disorder). Brookmeyer et al. investigated the national estimates of the prevalence of AD, 
concluding that at age of 70 years old, the prevalence is 0.13. Kamal et al.  (2012) used a 
cross sectional analysis with the AHS participants to investigate if pesticide exposure was 
associated with development of with amyotrophic lateral sclerosis (ALS), finding that the 
OR for ALS diagnosis was 1.6. While ALS is much less common than AD, this should 
provide a conservative basis for determining sample size for AD. 
For recruitment, 1500 Dicofol-exposed and unexposed participants from the AHS 
cohort will be approached to participate in the study in order to reach an appropriate 
sample size.  
	
Exposure assessment 
Half of the study sample will consist of pesticide applicators who reported being 
exposed to Dicofol on their enrollment take home questionnaire and the other half will 
consist of controls who did not report being exposed to Dicofol. This information will be 
obtained from the AHS “Take Home Applicator” data set (Agricultural Health Study, 
1993).  
Exposure or non-exposure to Dicofol will be based on participants’ answers to 
questionnaires about this exposure completed in 1993-1996 when the cohort was 
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assembled. It will be characterized as a binary exposure variable (yes/no), as no exposure 





The pesticide applicators and their spouses provided information on demographics such 
as chronic medical conditions, lifestyle (smoking history, alcohol and drug use etc.), 
specific pesticide use, agricultural hazards and practices through the self-administered 
questionnaires in the AHS (Agricultural Health Study, 1996; Alavanja et al., 1996). 
When approached about the current study, those agreeing to participate will complete 
updated questionnaires on these variables.  Access to their electronic medical record data 
(EMR) will also be requested to allow exclusion of participants who meet exclusion 




AD diagnosis will be determined in two ways. If EMR data for a participant indicate 
she/he has been diagnosed with AD, the participant will automatically be deemed as 
having the disease.  
 
Other participants will undergo a diagnostic assessment to determine whether diagnosis 
of presumptive AD is likely. The initial assessment will be conducted in the neurology 
study clinic and will include a neurological examination (consisting of assessing cranial 
nerves, gait, etc.) and use of the Mini-mental Status Examination (MMSE) to determine 
	
44 
likelihood of cognitive impairment consistent with AD. The clinic neurology specialist 
will assess the patient while considering their past medical history, a past surgical history, 
allergies, medications, and a social history. Participants identified through neurological 
examination and likely AD based on MMSE score will then undergo an Amyloid PET 
scan with study Radiology personnel in order to determine the presence of a heavy 
amyloid burden in areas such as the frontotemporal region of the brain, which has been 
shown to be associated with the diagnosis of AD. Criteria for deciding if there is enough 
amyloid burden will be decided by a licensed Radiologist. Participants who meet both 
MMSE cut-off criteria and amyloid PET criteria will be identified as AD cases. 
MMSE 




scores vary by years of formal education, education-adjustment cutoffs for AD on the 
MMSE will be: 22 or below among participants who completed 7th grade or less;  24 or 
less for those with an education of 8th grade or high school (without graduating); 25 or 
less among participants with a high school diploma; and 26 or less for those with a 
college education or higher. Scoring below the education-adjustment cutoffs indicates the 




Patients chosen from the AHS will be approached primarily by research and 
administrative personnel associated with the study using a developed script. Those 
consenting to be enrolled will be sent a packet consisting of a questionnaire involving 
different aspects of their lifestyles, as well as general information on the study such as the 
goals. A written consent form will be included in the packet with a return address back to 
the study’s personnel at one of the two designated sites.   
The study will maintain two project neurology clinics located in Iowa (Lutheran Hospital 
in Des Moines) and North Carolina (Wakemed Raleigh Hospital in Raleigh). Because 
patients will likely have been treated by various hospitals in Iowa and North Carolina, the 
electronic medical records (EMR) for each participant will be obtained after acquiring the 
written consent originally sent to each participant. If their EMRs confirm that they have 
no history of diagnoses meeting exclusionary criteria, they will be asked to come to the 
neurology clinic in their respective state for assessment (unless the EMR confirms 
existing AD diagnosis).  
 
Data analysis 
A chi-square analysis of the data will be used to determine a possible association between 
exposure status and AD diagnosis. Using the chi-square test, the association between 
categorical variables (whether the participant had been exposed to Dicofol in the past and 
diagnosis of AD or negative) will be explored. The proportion of participants with a 
positive AD diagnosis independent of Dicofol exposure and the proportion of participants 
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with a positive AD diagnosis associated with Dicofol exposure will be identified. In 
addition, because smoking, high cholesterol, and alcohol use may act as a confounder for 
the risk of developing AD, they will be adjusted for through stratification. It should also 
be noted that age is also a potential confounder, in which if one group has a larger 
proportion of older participants in comparison to the other group; the data may be altered.  
Timeline and resources 
Because the study is a retrospective cohort study, the timeline for this proposal is divided 
into three phases and will cover a 1-year period. 
Month 1-3 
Phase one of the study will include IRB application and approval. Resources such as 
study personnel hired for the project and approved by IRB will be assembled to begin 
recruitment. EMRs will be reviewed for each consenting participant. 
Month 4-8 
Once the required sample size is met, the second phase will require those selected to 
come be assessed at their closest study neurology clinic site, which will be used as an 
additional resource. The study neurological site teams will include a board-certified 
neurologist, Neurology PA, or Neurology NP to conduct neurological examination 
procedures and MMSEs. All travel expenses will be covered and each participant will 
receive a $100 gift card for their participation as incentive.  
Patients identified as likely AD through the neurological examination and MMSE will be 
undergo Beta Amyloid PET Scanning at a site staffed by radiologists and technicians 




Phase three of the study will consist of data analysis and preparation of publications. 
 
Institutional Review Board 
Participants are required to meet with a neurologist to assess cognition using the MMSE, 
as well as an Amyloid PET Scan to assess for Beta-Amyloid accumulation in the brain. 
Because those included in the AHS will need to be contacted and assessed in-person, the 
AHS data used will need to be re-identified. In addition, data will be collected through 
personal interaction with the participants by study personnel. Therefore, an IRB 
application would need to be submitted. The IRB proposal would likely be an expedited 
review. The expedited review would specifically be in the Collection of data through 
noninvasive procedures (not involving general anesthesia or sedation) routinely 
employed in clinical practice, excluding procedures involving x-rays or microwaves. 
category. The IRB approval must be obtained before the study begins.   
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